Full-Time

Technical Product Owner

Manufacturing Systems

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior, Expert

Hyderabad, Telangana, India

Category
Technical Product Management
Product
Requirements
  • Doctorate degree OR
  • Master’s degree and 4 to 6 years of Life Science/Biotechnology/Pharmacology/Information Systems experience OR
  • Bachelor’s degree and 6 to 8 years of Life Science/Biotechnology/Pharmacology/Information Systems experience OR
  • Diploma and 10 to 12 years of Life Science/Biotechnology/Pharmacology/Information Systems experience
  • Excellent problem-solving skills and a passion for tackling complex challenges in manufacturing with technology
  • Understanding of manufacturing technologies, systems, data and integrations
  • Collaborative spirit and effective communication skills to work seamlessly in a cross-functional team
  • An ongoing commitment to learning and staying at the forefront of technology, digital and AI advancements
  • Experience creating impactful slide decks and communicating data
Responsibilities
  • Manage a suite of custom internal platforms, commercial off-the-shelf (COTS) software, and systems integrations
  • Translate complex scientific and technological needs into clear, actionable requirements for development teams
  • Function as a Product Owner for Manufacturing Systems within a Scaled Agile Framework (SAFe) product team
  • Develop and maintain a product roadmap that clearly outlines the planned features and enhancements, timelines, and milestones
  • Collaborate with geographically dispersed teams, including those in the US and other international locations
  • Partner and ensure alignment of the Amgen India DTI site leadership and follow global standards and practices
  • Foster a culture of collaboration, innovation, and continuous improvement
  • Identify and manage risks associated with the systems, including technological risks, scientific validation, and user acceptance
  • Develop documentation, communication plans and training plans for end users
  • Ensure operational excellence, cybersecurity and compliance.
Desired Qualifications
  • Experience in implementing and supporting manufacturing systems.
  • Experience with Manufacturing Execution Systems (MES), Data Historians, Process Automation Systems or Industry 4.0 technologies.
  • Experience with cloud (e.g., AWS, Azure), on-premises and hybrid architecture.
  • SAFe for Teams certification (preferred)
  • SAFe Product Owner and SAFe Product Manager (preferred)
  • Experience with stakeholder management, managing a team, ensuring seamless coordination across teams and driving the successful delivery of technical projects
  • Familiarity with databases and analytics platform such as Databricks and related programming languages like SQL, Python.
  • Ability to drive projects/company initiatives using Agile methodology

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.